If you read my past articles, you know that Anavex Life Sciences has had some seemingly very successful drug trials for its new Alzheimer’s drug, Blarcamesine. The drug, which comes in a pill form (this is important), seems not only to slow the progression of Alzheimer’s among the trial patients in general, but it seems to have a very outsized effect on a select group of patients (the super-responders).
Anavex Life Sciences just hosted a quarterly corporate conference call on its pharmaceutical work and its financial situation. Here’s the update on Blarcamesine: